ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,127.79
      1.26%
      US Tech 100
      17,446.00
      2.17%
      Dow Jones
      38,675.68
      1.18%
      Brent Oil
      83.145
      0.02%
      Bitcoin
      64,326.17
      0.51%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. VistaGen Therapeutics Inc (VTGN)

      7. VistaGen Therapeutics Inc (VTGN) News

      VTGN

      VistaGen Therapeutics (VTGN)

      VistaGen Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:VTGN
      DateTimeSourceHeadlineSymbolCompany
      04/25/20248:30AMBusiness WireVistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental FatigueNASDAQ:VTGNVistaGen Therapeutics Inc
      04/09/20248:30AMBusiness WireVistagen to Present at the 2024 Anxiety and Depression Association (ADAA) ConferenceNASDAQ:VTGNVistaGen Therapeutics Inc
      04/01/20248:30AMBusiness WireVistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2NASDAQ:VTGNVistaGen Therapeutics Inc
      03/11/20248:30AMBusiness WireVistagen to Present at Stifel 2024 Virtual CNS DaysNASDAQ:VTGNVistaGen Therapeutics Inc
      03/06/20246:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistaGen Therapeutics Inc
      03/06/20246:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistaGen Therapeutics Inc
      03/06/20246:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistaGen Therapeutics Inc
      03/06/20246:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistaGen Therapeutics Inc
      03/01/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:VTGNVistaGen Therapeutics Inc
      02/28/20248:30AMBusiness WireVistagen to Present at TD Cowen 44th Annual Health Care ConferenceNASDAQ:VTGNVistaGen Therapeutics Inc
      02/14/20246:18PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VTGNVistaGen Therapeutics Inc
      02/14/20244:51PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:VTGNVistaGen Therapeutics Inc
      02/14/20248:56AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VTGNVistaGen Therapeutics Inc
      02/13/20244:52PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:VTGNVistaGen Therapeutics Inc
      02/13/20244:33PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTGNVistaGen Therapeutics Inc
      02/13/20244:25PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VTGNVistaGen Therapeutics Inc
      02/13/20244:20PMBusiness WireVistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate UpdateNASDAQ:VTGNVistaGen Therapeutics Inc
      02/12/20246:27PMEdgar (US Regulatory)Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:VTGNVistaGen Therapeutics Inc
      02/06/20248:30AMBusiness WireVistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024NASDAQ:VTGNVistaGen Therapeutics Inc
      01/03/20245:19PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistaGen Therapeutics Inc
      01/03/20245:17PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTGNVistaGen Therapeutics Inc
      01/03/20245:09PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTGNVistaGen Therapeutics Inc
      12/27/20238:30AMBusiness WireVistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic PainNASDAQ:VTGNVistaGen Therapeutics Inc
      11/09/20234:44PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VTGNVistaGen Therapeutics Inc
      11/09/20234:42PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTGNVistaGen Therapeutics Inc
      11/09/20234:30PMBusiness WireVistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial ResultsNASDAQ:VTGNVistaGen Therapeutics Inc
      11/08/20238:30AMBusiness WireVistagen to Present at Stifel 2023 Healthcare ConferenceNASDAQ:VTGNVistaGen Therapeutics Inc
      11/07/20238:30AMBusiness WireVistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific ConferencesNASDAQ:VTGNVistaGen Therapeutics Inc
      11/06/20239:46PMEdgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:VTGNVistaGen Therapeutics Inc
      11/06/20234:27PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTGNVistaGen Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:VTGN